StockData

Jyong Biotech Ltd. (MENS) stock

MENSNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026Score 0/30
$1.76+0.08 (+4.76%)

Close on Nov 13, 2026Market cap $133.81MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025

Valuation

Market cap
$133.81M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$4.67M
EPS, diluted
-$0.06

Trading

Previous close
$1.68
Open
$1.73
Day's range
$1.71 – $1.83
Volume
27,029
Average volume (20 days)
41,292
52-week range
$1.43 – $40.25
RSI (14 days)
44.7
Volatility (1 year)
152.5%
Relative volume
0.60×

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodMENSS&P 500DifferenceMENS per yearS&P 500 per year
1 month-13.7%-3.0%−10.7 pts
3 months-14.6%-2.8%−11.8 pts
Year to date-55.4%+11.5%−66.9 pts
1 year-95.4%+13.5%−108.9 pts

Four years at a glance

Fiscal years 2022 to 2025, USD

Operating income

-$2.61M

Net income

-$4.67M

EPS, diluted

-$0.06
Reported period

Press releases

Releases Jyong Biotech filed with the SEC as exhibits to Form 8-K or 6-K

About Jyong Biotech

Pharmaceutical Preparations

Jyong Biotech Ltd. is a clinical-stage biopharmaceutical company focused on the development of botanical drug products. The company's primary focus is on advancing its core drug candidate, Botreso, which is undergoing clinical development for the initial treatment of benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS). In addition to Botreso, the company explores other potential indications, such as prostate cancer prevention, as well as candidates designated as PCP and IC. Its future customer base encompasses prospective patients, healthcare providers, and third-party payors within the medical community.

Company profile, executives and history

Jyong Biotech stock: common questions

What is Jyong Biotech's stock price?

MENS closed at $1.76 on Nov 13, 2026, up 4.76% on the day. Over the past 52 weeks it traded between $1.43 and $40.25.

What is Jyong Biotech's market cap?

Jyong Biotech was worth $133.81M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.

What is MENS's P/E ratio?

Jyong Biotech lost money over fiscal 2025 (diluted EPS -$0.06), so it has no meaningful P/E ratio.

Does Jyong Biotech pay a dividend?

No. Jyong Biotech has not paid a cash dividend over the last twelve months.

How has MENS stock performed over the past year?

Including dividends, MENS returned -95.4% over the past year, against +13.5% for the S&P 500.

How many MENS shares are sold short?

0M shares were sold short at the latest FINRA report, 0.40% of the float, or 5.1 days of average trading volume.

Who are Jyong Biotech's competitors?

Companies most similar to Jyong Biotech by business, industry and size include ANL, NBP, APLM, COGT, PPBT.

See a number that looks wrong?